PPP1R7

Protein phosphatase 1 regulatory subunit 7 · Q15435 · PPP1R7 on Sugi Atlas →

0 patent compounds predicted against PPP1R7, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PPP1R7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis PHASE4COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer PHASE2COMPLETED
Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer PHASE2COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer PHASE1/PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) PHASE1/PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors PHASE1WITHDRAWN
Immune Signature of Palmoplantar Pustulosis nanCOMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Studying Phosphorus Metabolism nanCOMPLETED
IVF Outcome in Polycystic Ovary Syndrome Patients nanUNKNOWN
Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer nanCOMPLETED
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Protein Intake and Step Reduction in Older Adults nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PPP1R7 binder may also engage these)

ProteinNameSimilarity
Q5HZV9 1.000 Q5HZV9 →
Q5RFS7 1.000 Q5RFS7 →
Q6DIQ3 1.000 Q6DIQ3 →
Q3UM45 1.000 Q3UM45 →
Q3T0W4 1.000 Q3T0W4 →
Q32PL1 1.000 Q32PL1 →
P22194 0.995 P22194 →
P45969 0.987 P45969 →
Q84WJ9 0.984 Q84WJ9 →
Q54Q39 0.983 Q54Q39 →
P36047 0.983 P36047 →
Q8T888 0.981 Q8T888 →
Q9XHH2 0.981 Q9XHH2 →
Q6DHB1 0.978 Q6DHB1 →
Q28G94 0.975 Q28G94 →
Q641R9 0.975 Q641R9 →
O61967 0.974 O61967 →
Q05A62 0.974 Q05A62 →
SNRPA1 U2 small nuclear ribonucleoprotein A' 0.974 landscape →
Q4R8Y8 0.972 Q4R8Y8 →
Q4LDG9 0.972 Q4LDG9 →
Q8TCA0 0.972 Q8TCA0 →
Q9BLB6 0.971 Q9BLB6 →
Q2KID4 0.971 Q2KID4 →
Q8CI70 0.969 Q8CI70 →
A0A096MJZ0 0.968 A0A096MJZ0 →
P57784 0.968 P57784 →
Q4WV66 0.968 Q4WV66 →
Q6C417 0.968 Q6C417 →
Q4P5F9 0.967 Q4P5F9 →